BRIEF—Sanifit raises $80 million in series D round

Sanifit has raised around $80 million in a series D financing round, led by Spain’s Caixa Capital Risc.

Sanifit, which is focused on treatments for progressive vascular calcification disorders, will use the money to develop its lead candidate SNF472 for the treatment of the serious and rare condition calcific uremic arteriolopathy (CUA).

The therapy has orphan drug designation in the USA and Europe, and will enter Phase III testing later this year.